• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

pSivida Corp.

pSivida buys Icon Bioscience and rebrands as EyePoint Pharmaceuticals

March 29, 2018 By Sarah Faulkner

With the help of $61 million from EW Healthcare Partners and a third-party investor, pSivida (NSDQ:PSDV) announced today that it acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. The two companies combined and plan to do business as EyePoint Pharmaceuticals. pSivida also landed a $20 million debt facility from SWK Holdings Corp., to […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Mergers & Acquisitions, Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: iconbioscience, pSivida Corp.

FDA to review pSivida’s ocular drug-delivery system

March 20, 2018 By Sarah Faulkner

pSivida (NSDQ:PSDV) said yesterday that the FDA plans to review the company’s application for its drug-releasing ocular insert, Durasert. The product is designed to provide three years of treatment for patients with posterior segment uveitis. The U.S. regulatory agency is slated to decide whether or not to approve pSivida’s new drug application by Nov. 5. Get […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: pSivida Corp.

pSivida touts 12-month data from Ph3 trial of Durasert ocular insert

February 8, 2018 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted results today from a second Phase III trial that the company conducted for its three-year posterior segment uveitis treatment. The 153-patient study found that there was a significant reduction in the recurrence of posterior segment uveitis through 12 months in the group treated with pSivida’s drug-releasing ocular insert, Durasert. Get the full story […]

Filed Under: Clinical Trials, Drug-Device Combinations, MassDevice Earnings Roundup, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: pSivida Corp.

pSivida seeks FDA nod for 3-year treatment of posterior segment uveitis

January 8, 2018 By Sarah Faulkner

pSivida (NSDQ:PSDV) has submitted a new drug application to the FDA for its Durasert implant that provides three years of treatment for people with posterior segment uveitis. The drug-delivery product’s NDA includes data from two Phase III trials, both of which met their primary efficacy endpoints after six months. Get the full story at our sister […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: pSivida Corp.

pSivida touts pilot osteoarthritis trial for Durasert implant

December 14, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted results today from a Phase I safety and efficacy pilot trial of its sustained-release Durasert implant in patients with osteoarthritis of the knee. The company’s Durasert tech, combined with an implantable device from the Hospital for Special Surgery, was designed to continuously deliver a low dose of dexamethasone into the knee joint. Six patients […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Orthopedics, Pharmaceutical, Wall Street Beat Tagged With: pSivida Corp.

pSivida licenses European rights for Durasert to Alimera

July 11, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) said today that it restructured a deal with Alimera Sciences (NSDQ:ALIM) to grant Alimera rights to the Durasert three-year treatment for posterior segment uveitis in Europe, the Middle East and Africa. Alimera, which holds an exclusive license to pSivida’s intravitreal implant, Iluvien, plans to apply for a secondary indication for Iluvien for posterior segment uveitis. Get […]

Filed Under: Drug-Device Combinations, Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: pSivida Corp.

pSivida seeks European regulatory nod for Durasert

June 22, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) is looking to market its Durasert 3-year treatment for posterior segment uveitis in the European Union. Today, the Watertown, Mass.-based company submitted a marketing authorization application to the European Medicines Agency. Earlier this month, pSivida reported that its 2nd Phase III trial, which followed patients for 3 years, met its primary endpoint of […]

Filed Under: Drug-Device Combinations, Implants, Optical/Ophthalmic, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: pSivida Corp.

pSivida implant meets primary endpoint in late-stage trial

June 14, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months. In the 153-patient trial, 21.8% of Durasert-treated patients had a […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Optical/Ophthalmic, Pharmaceutical, Wall Street Beat Tagged With: pSivida Corp.

Study: pSivida’s Durasert lessens recurrence of uveitis through 12 months

May 9, 2017 By Sarah Faulkner

pSivida (NSDQ:PSDV) touted 1-year follow-up data yesterday for the company’s Durasert 3-year treatment of posterior segment uveitis. The data, which was presented at the Association for Research in Vision and Ophthalmology annual meeting, is from pSivida’s 1st phase III trial. The data showed that the 3-year uveitis implant significantly reduced the recurrence of posterior segment uveitis […]

Filed Under: Clinical Trials, Drug-Device Combinations, Implants, Optical/Ophthalmic, Wall Street Beat Tagged With: pSivida Corp.

pSivida shares gain on Q2 earnings

February 9, 2017 By Sarah Faulkner

Shares in pSivida (NSDQ:PSDV) rose yesterday after the medical device maker met expectations on Wall Street with its fiscal 2nd quarter results. The Watertown, Mass.-based company pared its losses to -$0.1 million, or 0¢ per share, on sales of $6 million for the 3 months ended Dec. 31, for bottom-line growth of 98.7% on sales […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Optical/Ophthalmic Tagged With: pSivida Corp.

pSivida misses Q3 estimates, profits slide 47%

November 8, 2016 By Sarah Faulkner

Shares in pSivida (NSDQ:PSDV) fell 6% today after the company missed expectations on Wall Street with its fiscal 1st-quarter results. The Watertown, Mass.-based company posted losses of -$7.2 million, or -21¢ per share, on sales of $277,000 for the 3 months ended Sept. 30, for a bottom-line loss of -47% on a  -41% sales decline, compared […]

Filed Under: Drug-Device Combinations, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: pSivida Corp.

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS